Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Chief Medical Officer | January 22, 2024 | January 23, 2024 |
| MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359 | Chief Medical Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date January 22, 2024 · Filed January 23, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2034-01-21 | Direct | 285,000 |
Reported balance
After 2024-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-22 · Grant · Acquired 285,000 · Balance 285,000 F1: Vests with respect to 25% of the underlying common shares on January 22, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on April 1, 2025. |
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2024-01-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Vests with respect to 25% of the underlying common shares on January 22, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on April 1, 2025.
MARINUS PHARMACEUTICALS, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2029-08-21 | Direct | 60,000 |
Reported balance
After 2019-08-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-08-21 · Grant · Acquired 60,000 · Balance 60,000 F1: Options to purchase shares of common stock vest monthly in 36 equal installments beginning 8/31/19. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase shares of common stock vest monthly in 36 equal installments beginning 8/31/19.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 2,000 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 · Expires 2031-03-17 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Grant · Disposed 5,000 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2024 Filed Jan 23, 2024 16:23 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock option (right to buy) · Derivative | 285,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001235802-24-000015 · primary_doc.xml · derivative · entry 2 Lorianne Masuoka K. · CIK 0001466086 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Shares · 285,000 shares Expires 2034-01-21 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on January 22, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on April 1, 2025. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:05 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001385508-23-000059 · wf-form4_167785233655513.xml · derivative · entry 3 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:05 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 2,000 | $20.00 | $40,000.00 |
DisclosureSEC source: 0001385508-23-000059 · wf-form4_167785233655513.xml · nonDerivative · entry 2 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 09:05 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Disposition to issuerCommon Stock | 2,000 | $20.00 | $40,000.00 |
DisclosureSEC source: 0001385508-23-000059 · wf-form4_167785233655513.xml · nonDerivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 16:55 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-22-000086 · wf-form4_165524014507774.xml · nonDerivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. F1 · shares: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:04 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001385508-21-000084 · wf-form4_162387383591827.xml · nonDerivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2022 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 16:10 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001385508-21-000052 · wf-form4_161644379924757.xml · derivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-03-17 F1 · derivative.exercise_date: One-third of the shares subject to the option vest on March 18, 2022 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:05 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001104659-19-047144 · a4.xml · derivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-08-21 F1 · derivative.exercise_date: Options to purchase shares of common stock vest monthly in 36 equal installments beginning 8/31/19. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 19:00 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001104659-19-011640 · a4.xml · derivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: 11,111 options to purchase shares of common stock vest immediately on 2/26/19. The remainder vest in 34 equal monthly installments commencing 3/1/2019. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 16:06 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $6.19 | $0.00 |
DisclosureSEC source: 0001104659-17-072520 · a4.xml · derivative · entry 1 Lorianne Masuoka K. · CIK 0001466086 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Options to purchase shares of common stock vest in 36 equal monthly installments commencing 1/1/2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.